Photocure and Artera to partner on digital pathology AI test evaluation for Bladder Cancer

OSLO, Norway, June 8, 2026 /PRNewswire/ -- Photocure ASA (OSE: PHO), the Bladder Cancer Company, and Artera, a leading precision medicine company, announce launch of a joint research initiative. The collaboration encompasses Photocure's blue light cystoscopy (BLC) registry in bladder cancer and the ArteraAI Bladder Test, an AI-powered digital pathology test currently in development for patients with bladder cancer.

As healthcare systems increasingly embrace precision medicine, the demand for advanced precision diagnostics in uro-oncology continues to grow. Photocure, already recognized for its proven leadership in bladder cancer diagnostics where accuracy is critical, is well positioned to meet this need. This research initiative with Artera underscores Photocure's commitment to grow an array of complementary diagnostic solutions to address the evolving needs of patients, physicians, and the broader healthcare community, towards more personalized, data-driven care in uro-oncology, enabling better clinical outcomes and supporting the shift toward precision medicine.

The research collaboration will provide Artera with access to high-quality data from the Photocure U.S. BLC registry to further validate the ArteraAI Bladder Test. Together, the companies will utilize real world evidence to help urologists more effectively identify bladder cancer and manage its treatment. Unlike many other cancers, there are fewer well-established biomarkers in bladder cancer, which currently limits clinicians from personalizing treatment options. The partnership between Photocure and Artera is dedicated to advancing research that guides smarter treatment decisions and helps patients receive therapies best suited to their disease.

The objectives of using the BLC registry's long-term clinical practice data are to develop, evaluate, and optimize the performance of Artera's multimodal AI (MMAI) histopathology biomarkers in patients with non-muscle invasive bladder cancer (NMIBC). The joint research aims to validate the prognostic and predictive capabilities of the ArteraAI Bladder by addressing critical clinical questions.

"With this collaboration, we are exploring additional ways to enter scientific collaborations that may utilize Photocure's BLC registry to advance the field of precision diagnostics. When urologists use BLC, they often perform biopsies and resection to achieve a more accurate diagnosis and a more complete procedural outcome. By pairing the BLC captured specimen with the ArteraAI Bladder Test, we aim to accurately determine the grade and stage of disease while also providing a readout on whether these patients are optimal candidates for specific follow-up drug therapy. BLC and Artera's AI-powered biomarkers have the promise to set patients on the right course of bladder cancer management, streamlining the decision-making for pathologists and urologists," said Anders Neijber, Chief Medical Officer of Photocure.

Schreibe Deinen Kommentar